UY32753A - NUEVOS DERIVADOS DE 2,3-DIHIDRO-1H-IMIDAZO{1,2-a}PIRIMIDIN-5-ONA, SU PREPARACIÓN Y SU UTILIZACIÓN EN FARMACÉUTICA - Google Patents

NUEVOS DERIVADOS DE 2,3-DIHIDRO-1H-IMIDAZO{1,2-a}PIRIMIDIN-5-ONA, SU PREPARACIÓN Y SU UTILIZACIÓN EN FARMACÉUTICA

Info

Publication number
UY32753A
UY32753A UY0001032753A UY32753A UY32753A UY 32753 A UY32753 A UY 32753A UY 0001032753 A UY0001032753 A UY 0001032753A UY 32753 A UY32753 A UY 32753A UY 32753 A UY32753 A UY 32753A
Authority
UY
Uruguay
Prior art keywords
pirimidin
dihidro
ona
imidazo
pharmaceutical
Prior art date
Application number
UY0001032753A
Other languages
English (en)
Inventor
Baptiste Ronan
Annie Clauss
Gilbert Marciniak
Bertrand Vivet
Halley Frank
Maurice Brollo
El Ahmad Youssef
Laurent Schio
Fabrice Viviani
Andre Zimmermann
Karlsson Karl Andreas
Filoche-Romme Bruno
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0903236A external-priority patent/FR2947550B1/fr
Priority claimed from FR0957067A external-priority patent/FR2951173B1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY32753A publication Critical patent/UY32753A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a los nuevos productos de la fórmula (I): en la que representa L-arilo o L-heteroarilo opcionalmente sustituidos, tal que L representa: alquilo o CO o L´-X con L´ que representa alquilo y X representa O o S; R representa H o alquilo; R3 representa alquilo eventualmente sustituido por Hal; R4 representa H o Hal; estando estos productos en todas las formas isómeras y las sales, como medicamentos principalmente como inhibidores de fosforilación de AKT(PKB)
UY0001032753A 2009-07-02 2010-07-02 NUEVOS DERIVADOS DE 2,3-DIHIDRO-1H-IMIDAZO{1,2-a}PIRIMIDIN-5-ONA, SU PREPARACIÓN Y SU UTILIZACIÓN EN FARMACÉUTICA UY32753A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0903236A FR2947550B1 (fr) 2009-07-02 2009-07-02 Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
US24109709P 2009-09-10 2009-09-10
FR0957067A FR2951173B1 (fr) 2009-10-09 2009-10-09 Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)

Publications (1)

Publication Number Publication Date
UY32753A true UY32753A (es) 2011-01-31

Family

ID=43127464

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032753A UY32753A (es) 2009-07-02 2010-07-02 NUEVOS DERIVADOS DE 2,3-DIHIDRO-1H-IMIDAZO{1,2-a}PIRIMIDIN-5-ONA, SU PREPARACIÓN Y SU UTILIZACIÓN EN FARMACÉUTICA

Country Status (25)

Country Link
US (1) US8828997B2 (es)
EP (1) EP2448939B1 (es)
JP (1) JP5663571B2 (es)
KR (1) KR101745028B1 (es)
CN (1) CN102482285B (es)
AR (1) AR077446A1 (es)
AU (1) AU2010267814B2 (es)
BR (1) BRPI1015949A2 (es)
CA (1) CA2767051C (es)
CY (1) CY1119442T1 (es)
DK (1) DK2448939T3 (es)
ES (1) ES2627428T3 (es)
HR (1) HRP20170827T1 (es)
HU (1) HUE034503T2 (es)
IL (1) IL217294A (es)
LT (1) LT2448939T (es)
MX (1) MX2012000097A (es)
PL (1) PL2448939T3 (es)
PT (1) PT2448939T (es)
RU (1) RU2554868C2 (es)
SG (2) SG177421A1 (es)
SI (1) SI2448939T1 (es)
TW (1) TWI458730B (es)
UY (1) UY32753A (es)
WO (1) WO2011001112A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2969612B1 (fr) * 2010-12-23 2013-02-08 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique
WO2012085244A1 (fr) * 2010-12-23 2012-06-28 Sanofi Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
HUE036052T2 (hu) 2011-12-15 2018-06-28 Novartis Ag PI3K aktivitással vagy funkcióval rendelkezõ inhibitorok alkalmazása
FR2992314B1 (fr) * 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
FR2992316A1 (fr) * 2012-06-22 2013-12-27 Sanofi Sa Derives de pyrimidinones, leur preparation et leur application en therapeutique
MX2017009525A (es) * 2015-01-23 2018-04-10 Glaxosmithkline Ip Dev Ltd Derivado de pirazolo[3,4-d]pirimidina y su uso para el tratamiento de leishmaniasis.
KR102652898B1 (ko) * 2015-08-07 2024-04-01 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 화합물
JP2019086340A (ja) * 2017-11-02 2019-06-06 シスメックス株式会社 細胞検出方法および細胞検出システム
WO2022093820A1 (en) * 2020-10-28 2022-05-05 Genentech, Inc. Substituted morpholine compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5888381A (ja) * 1981-11-24 1983-05-26 Ube Ind Ltd イミダゾピリミジン類
US20020077327A1 (en) * 1999-09-23 2002-06-20 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
MY125533A (en) * 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
JP4820518B2 (ja) 2000-01-24 2011-11-24 アストラゼネカ アクチボラグ モルホリノ置換化合物治療薬
EP1184384A1 (en) * 2000-09-01 2002-03-06 Sanofi-Synthelabo 1-(Alkyl), 1-((heteroaryl)alkyl) and 1-((aryl)alkyl)-7-pyridin-4-ylimidazo(1,2a)pyrimidin-5(1H)-one derivatives
AR030587A1 (es) * 2000-09-01 2003-08-27 Sanofi Aventis Derivados de 2-piridinil-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona y 7-piridinil-2,3-dihidroimidazo[1,2-a]pirimidin-5(1h)-ona
GB0119865D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
EP1340761A1 (en) 2002-02-28 2003-09-03 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives
CN1247585C (zh) * 2001-09-21 2006-03-29 赛诺菲安万特 取代的2－吡啶基－6,7,8,9－四氢嘧啶并[1,2－a]嘧啶－4－酮及7－吡啶基－2,3－二氢咪唑并[1,2－a]嘧啶－5(1h)酮衍生物
AU2003221500B9 (en) 2002-02-28 2008-11-20 Mitsubishi Pharma Corporation Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl -6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
EP1340759A1 (en) * 2002-02-28 2003-09-03 Sanofi-Synthelabo 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives
JP4646626B2 (ja) 2002-08-16 2011-03-09 アストラゼネカ アクチボラグ ホスホイノシチド３−キナーゼβの阻害
CN1898243A (zh) * 2003-12-23 2007-01-17 诺瓦提斯公司 二环杂环类p－38激酶抑制剂
AR054438A1 (es) 2005-04-15 2007-06-27 Kudos Pharm Ltd Inhibidores de adn -pk
EP1895997A2 (en) * 2005-05-26 2008-03-12 Kudos Pharmaceuticals Ltd Use of dna-pk inhibition to sensitise atm deficient cancers to dna-damaging cancer therapies
WO2008064244A2 (en) 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
WO2008148074A2 (en) 2007-05-24 2008-12-04 Research Foundation Of State University Of New York Inhibitors of mtor and methods of treatment using same

Also Published As

Publication number Publication date
TWI458730B (zh) 2014-11-01
SG10201403138WA (en) 2014-08-28
US20120142679A1 (en) 2012-06-07
LT2448939T (lt) 2017-06-12
WO2011001112A1 (fr) 2011-01-06
IL217294A0 (en) 2012-02-29
EP2448939A1 (fr) 2012-05-09
ES2627428T3 (es) 2017-07-28
CN102482285A (zh) 2012-05-30
AU2010267814B2 (en) 2015-07-16
EP2448939B1 (fr) 2017-03-01
JP5663571B2 (ja) 2015-02-04
PL2448939T3 (pl) 2017-08-31
DK2448939T3 (en) 2017-06-19
KR20120103552A (ko) 2012-09-19
IL217294A (en) 2015-07-30
TW201105672A (en) 2011-02-16
CN102482285B (zh) 2015-07-15
US8828997B2 (en) 2014-09-09
SI2448939T1 (sl) 2017-06-30
KR101745028B1 (ko) 2017-06-08
PT2448939T (pt) 2017-06-12
RU2012103460A (ru) 2013-08-10
HUE034503T2 (en) 2018-02-28
CA2767051A1 (fr) 2011-01-06
HRP20170827T1 (hr) 2017-08-25
MX2012000097A (es) 2012-02-28
CY1119442T1 (el) 2018-03-07
BRPI1015949A2 (pt) 2016-04-26
AR077446A1 (es) 2011-08-31
JP2012531462A (ja) 2012-12-10
AU2010267814A1 (en) 2012-02-16
SG177421A1 (en) 2012-02-28
RU2554868C2 (ru) 2015-06-27
CA2767051C (fr) 2017-08-22

Similar Documents

Publication Publication Date Title
UY32753A (es) NUEVOS DERIVADOS DE 2,3-DIHIDRO-1H-IMIDAZO{1,2-a}PIRIMIDIN-5-ONA, SU PREPARACIÓN Y SU UTILIZACIÓN EN FARMACÉUTICA
CO6331467A2 (es) Nuevos derivados de imidazo(1,2-a)piridina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion particularmente como inhibidores de met
CO6331463A2 (es) Nuevos derivados de triazolo(4,3-a)piridina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion particularmente como inhibidores de met
DOP2018000153A (es) Derivados de 4-amino-2-(1h-pirazolo[3,4-b]piridina-3-il)-6-oxo-6,7-dihidro-5h-pirrolo[2,3-d] pirimidina y los respectivos derivados de (1h-indazol-3-il) como moduladores cgmp para el tratamiento de enfermedades cardiovasculares
DOP2012000310A (es) Morfolinopirimidinas y su uso en terapia
ECSP15048122A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
CO6741203A2 (es) Derivados de biciclo[3,2,1]octilamida y sus usos
UY33937A (es) Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
ECSP11011391A (es) Métodos y productos intermedios para preparar agentes farmacéuticos
UY31918A (es) Compuestos de pirazol inhibidores de fgfr, composiciones farmaceuticas que los comprenden, procesos para su preparacion y su uso como medicamento
NI201100020A (es) NUEVOS DERIVADOS DE IMIDAZO[1,2-a] PIRIMIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACIÓN COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACIÓN PARTICULARMENTE COMO INHIBIDOR DE MET.
UY33500A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
ECSP13012362A (es) Derivados de indolizina, su procedimiento de preparación
UY33501A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
CR20140134A (es) Composiciones farmacéuticas
CR20140218A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas iii
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
CR20140217A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas ii
CO6480974A2 (es) Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparación y su utilización farmacéutica como inhibidores de fosforilación de akt(pkb)
UY32754A (es) NUEVOS DERIVADOS DE 1,2,3,4-TETRAHIDRO-PIRIMIDO{1,2-a}PIRIMIDIN-6-ONA, SU PREPARACIÓN Y SU UTILIZACIÓN EN FARMACÉUTICA
UY33299A (es) Derivados de 6-(alquil-o cicloalquil-triazolopiridacina-silfanil)benzotiazoles:preparacion, aplicación como medicamentos y utilizacion como inhibidores de la met
UY32422A (es) Derivados de 6-(6-sustituido-triazlopiridacina-sulfanil) 5-fluoro-benzotiazololes y 5-fluoro-bencimidazoles : preparacion, aplicacion como medicamentos y utilizacion como inhibidores de met
UY32420A (es) Derivados de 6-(6-sustituido-triazolopiridazina-sulfanil)benzotiazoles y bencimidazoles : preparacion, aplicacion como medicamentos y utilizacion como inhibidores de met

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190211